Lamotrogine funding switch – Our response to the change

The Epilepsy Waikato Charitable Trust has concerns over the possible consequences of PHARMAC’s switch to fund one brand of Lamotrogine (Logem), which has recently been in the news.

Below is our response to this change with letters sent to PHARMAC and the NZ Herald expressing these concerns.

1. Letter to Pharmac_EWCT_25 September_2018

2. Letter to Pharmac_EWCT_12 October 2019

3. Letter to Pharmac _EWCT_18 December 2019

4. EWCT letter to NZ Herald_re_Pharmac switch and Peter Davies letter

5. Letter to Health Committee_EWCT_20 July 2020

6. Letter to Health Committee_clonazepam_phenobarbitone_EWCT_12 Aug 2020

7. Letter to the Ministry of Health 2021 re brand switch of ASMs_EWCT

8. Letter to Maria Lowe from Hon. Andrew Little – Sept 2021

Last modified: September 22nd, 2021 by EWCT | Posted in: News